Florica Therapeutics, Inc. selected for National Science Foundation Innovation Corps

Our Bureau

Florica Therapeutics, Inc. is pleased to announce being selected to participate in the National Science Foundation Innovation Corps (I-Corps) national program. The NSF I-Corps program is an intensive seven-week innovation and entrepreneurship training course aimed at identifying product-market fit. Recipients are provided with training, mentorship and $20,000 in NSF funding. “We are […]

Microalgae Could Hold Promise for IBD

Our Bureau

Microalgae cultivation start-up Yemoja, Ltd. is joining the MIGAL Galilee Research institute to spearhead an extensive, four-year research initiative to identify algae-sourced compounds with the potential to help manage inflammation and Inflammatory Bowel Disease (IBD). Select beneficial algae will be developed into functional foods as well as nutraceutical and pharmaceutical […]

AKAY-Spiceuticals substantiates FENUMAT-Capsaicin as the first Natural and Vegan ‘Bioavailable Capsaicinoids’ following a sustained-intestinal delivery approach

Our Bureau

Intestinal delivery with enhanced bioavailability is of great significance for stomach irritating and pungent bioactive molecules like Capsaicinoids from red chili peppers. Because, oral delivery is the one and only approved and preferred route of administration for nutrients (Nutraceuticals and Functional foods). But, there exist many challenges for pungent capsaicinoids.  […]

Aster Medcity doctor’s gift a new lease of life to 38-year-old Farooq who was suffering from rare post-Covid bowel gangrene complications

Our Bureau

Farooq. V, a 38-year-old native hailing from Ponnani, Malappuram is an exceptional survivor of a disease that has an otherwise very high death rate, said Dr. Prakash K, Senior Consultant Gastro Surgery, Aster Medcity, Kochi. It is known that Covid-19 affects the lungs, kidneys and various other organs. Blockage of blood […]

RedHill Biopharma’s Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant

Our Bureau

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing strong inhibition by opaganib (ABC294640)[1] of Delta variant replication while maintaining cell viability at relevant concentrations. Working with the University of Louisville Center for Predictive Medicine, opaganib […]

Subscribe Now